Clinical Trials Directory

Trials / Withdrawn

WithdrawnNCT04833959

Pilot Study of 89-Zr Panitumumab in Pancreas Cancer

Pilot Study of 89Zr Panitumumab in Pancreas Cancer

Status
Withdrawn
Phase
Phase 1
Study type
Interventional
Enrollment
0 (actual)
Sponsor
Stanford University · Academic / Other
Sex
All
Age
19 Years
Healthy volunteers
Not accepted

Summary

The main purpose of the study is to assess the safety of 89Zr-panitumumab as a molecular imaging agent in patients with (metastatic) pancreas cancer.

Conditions

Interventions

TypeNameDescription
DRUG89Zr-panitumumabImaging Agent

Timeline

Start date
2021-03-26
Primary completion
2024-03-01
Completion
2024-03-01
First posted
2021-04-06
Last updated
2024-06-21

Locations

1 site across 1 country: United States

Regulatory

Source: ClinicalTrials.gov record NCT04833959. Inclusion in this directory is not an endorsement.

Pilot Study of 89-Zr Panitumumab in Pancreas Cancer (NCT04833959) · Clinical Trials Directory